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Donor platelet plasma components inactivate
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One sentence summary: Protein fractionation of donor platelet plasma reveals that the primary inhibitors of Acinetobacter baumannii growth are
complement and a heat-stable fast form of alpha-2 macroglobulin.
Editor: Patrick Brennan
ABSTRACT
Acinetobacter baumannii is an environmentally resilient healthcare-associated opportunistic pathogen responsible for
infections at many body sites. In the last 10 years, clinical strains resistant to many or all commonly used antibiotics have
emerged globally. With few antimicrobial agents in the pharmaceutical pipeline, new and alternative agents are essential.
Platelets secrete a large number of proteins, including proteins with antimicrobial activity. In a previous study, we
demonstrated that donor platelet supernatants and plasma significantly inhibited the growth of a reference strain of A.
baumannii in broth and on skin. This inhibition appeared to be unrelated to the platelet activation state. In this study, we
demonstrate that this growth inhibition extends to clinical multidrug resistant isolates. We also demonstrate that there is
no relationship between this activity and selected platelet-derived antimicrobial proteins. Instead, the donor plasma
components complement and alpha-2 macroglobulin are implicated.
Keywords: platelets; plasma; growth inhibition; antimicrobial peptides; multidrug resistance; Acinetobacter baumannii
Acinetobacter baumannii is primarily found in healthcare set-
tings worldwide (Dijkshoorn, Nemec and Seifert 2007) and
causes pneumonia and bacteremia as well as central ner-
vous system, skin, bone and soft tissue infections (Peleg,
Seifert and Paterson 2008). Isolates can be resistant to all
commonly used gram-negative antimicrobial agents. With very
few treatment options, the development of new antimicro-
bial agents is imperative (Boucher et al. 2013; Roca et al.
2015).
Platelet gel or platelet-rich plasma is composed of concen-
trated activated platelets in donor plasma. When activated,
platelets secrete a variety of proteins and other molecules,
including antimicrobial peptides (AMPs). These AMPs include
platelet factor 4 (PF-4)/CXCL-4 (Yeaman et al. 1997), the pro-
teolytic derivatives of platelet basic protein (PBP/CXCL-7/β-
thromboglobulin), thrombocidins 1 and 2 (TC-1and TC-2) (Kri-
jgsveld et al. 2000), RANTES/CCL-5 (Tang, Yeaman and Selsted
2002), thymosin β4 (Tβ4) (Tang, Yeaman and Selsted 2002) and
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IL-8/CXCL-8 (Yount et al. 2007). A previous study established
that human donor platelet gel supernatants exhibited antimi-
crobial properties against A. baumannii (Edelblute et al. 2015).
Here, we hypothesize that platelet-produced AMPs are responsi-
ble for this inhibition and investigate individual platelet gel com-
ponents.
One-day expired single-donor platelets were purchased from
the American Red Cross (Norfolk, VA). Washed platelets were
activated with 100 US units mL−1 bovine thrombin or by
the application of nanosecond pulsed electric fields (5 pulses,
30 kV/cm 300 ns, 2 Hz, PEFs) as previously described (Edelblute
et al. 2015). After clotting, the samples were centrifuged and the
supernatants were assayed to avoid direct platelet activation by
bacteria (Cox, Kerrigan and Watson 2011). In this study, the sep-
arated plasma was referred to as ‘donor plasma’ to distinguish
it from normal human plasma.
Regardless of activation state, platelet supernatants signifi-
cantly inhibited the growth of several clinical A. baumannii iso-
lates. This inhibition of individual isolates was consistent across
the donor samples (Fig. 1). Quiescent and PEF-activated, but
not thrombin-activated, supernatants significantly inhibited the
growth of isolate 2 with respect to the control. Isolates 3, 4 and
8 were sensitive to quiescent and thrombin-activated, but not
PEF-activated, supernatants. The growth of isolates 5 and 7 was
significantly inactivated by all supernatants. Isolates 1, 6 and
9 were not significantly inhibited by any platelet supernatant.
This activity was stable after supernatant exposure to 56◦C for
30 minutes.
Interestingly, donor plasma significantly inhibited the
growth of eight of the nine clinical isolates, including the six
MDR isolates. Therefore, the concentration of the inactivat-
ing agent or agents must be highest in the donor plasma.
Heat inactivation reduced growth inhibition from 97 to 62%
(P < 0.001) (data not shown), implicating the activity of
complement, an innate, heat labile plasma component with
non-specific antibacterial activity. Several groups have demon-
strated that serum complement kills A. baumannii reference
strains, including ATCC 19606, and clinical isolates (Cervi and
Monetto 1996; Garcia et al. 2000; Kim et al. 2009; King et al. 2009).
The loss of killing after heat exposure implicates activation of
the alternative pathway (Cervi and Monetto 1996; Kim et al.
2009; King et al. 2009). However, the residual activity in donor
plasma must be attributed to a heat-stable component.
Inhibition of A. baumannii by AMPs was first described in
2000 (Giacometti et al. 2000), and platelet-derived AMPs could
account for the heat-stable antimicrobial activity. Four of these
proteins were quantified in platelet gel supernatants and in
donor plasma (Fig. 2). Levels of RANTES, NAP-2/TC-1 and IL-8
were significantly increased by thrombin activation with respect
to quiescent platelet gel supernatants. Although PEF applica-
tion induced platelet aggregation as observed previously (Zhang
et al. 2008), no significant increase in AMP levels was detected.
Donor plasma contained a significantly reduced concentration
of RANTES but a significantly greater concentration of PF-4 than
the supernatants, initially implicating PF-4 as an inactivating
agent. Platelet-produced PF-4 and its derived peptides are well-
studied AMPs (Yeaman et al. 1997; Yeaman 2010) particularly
against Staphylococcus aureus.
Growth inhibition of A. baumannii (ATCC 19606) and control
strains B. subtilis (ATCC 6633) and E. coli (ATCC 25922) by re-
combinant proteins was assayed at the highest mean concen-
tration detected in any sample type (Fig. 3a). Since increases in
concentration for the quantified analytes varied between 2-fold
(RANTES), 3-fold (NAP-2/TC-1), 7-fold (IL-8) and 2000-fold (PF-4)
over normal serum or plasma levels and Tβ4 was not quanti-
fied, this protein was tested at concentration of approximately
10-fold its normal serum concentration (Weller et al. 1988) In ini-
tial studies, PF-4 significantly inhibited the growth ofA. bauman-
nii and B. subtilis. However, when additional formulations of PF-4
were tested at the same concentration, including an alternative
human PF-4, mouse PF-4 and PF-4 (58-70), a peptide with known
antimicrobial activity (Darveau et al. 1992), no growth inhibition
was detected (Fig. 3b).
To better identify the heat-stable source of growth inhibition,
a supernatant samplewas fractionatedwith size exclusion chro-
matography. Activity was found in the fractions eluted between
7 and 10 ml of elution volume. These fractions inhibited growth
by 30% (Fig. 4) and corresponded to an apparent molecular
weight ranging between 400 and 800 kDa. SDS PAGE analysis of
the active fractions revealed the presence of multiple proteins,
so ion exchange chromatography was applied to the pooled ac-
tive fractions to reduce this number for identification analysis.
Figure 1. Growth inhibition of clinical A. baumannii isolates by platelet supernatants and donor plasma. Multidrug sensitive and resistant clinical A. baumannii isolates
were cultured from urine, wounds, sputum or the nose of different patients at a local hospital. Identification and antibiotic susceptibilities were determined using
a Vitek 2 system (bioMerieux, Durham, NC). Growth of 1000 colony forming units incubated 18 hours with peptides in Mueller Hinton broth (Hancock 2001) was
monitored by changes in OD620 and compared to control growth. Quiescent, quiescent platelet supernatant; thrombin, thrombin-activated platelet supernatant; PEFs,
PEF-activated platelet supernatant; DP, donor plasma. Mean ± SEM, n = 5–6 donors per group. ∗P < 0.05; ∗∗P < 0.01 with respect to quiescent supernatants.
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Figure 2.Quantification of AMPs in platelet gel supernatants and platelet plasma. Proteins were quantified using a bead-basedmultiplex assay (EMDMillipore, Billerica,
MA, MAGPIX platform, Luminex Corp., Austin, TX). A, RANTES; B, IL-8; C,CXCL7/NAP2; D, PF-4; E, HP. Q, quiescent platelet supernatant; C, supernatant from platelets
enriched with CaCl2; T, thrombin-activated platelet supernatant; PEFs, PEF-activated platelet supernatant; DP, donor plasma. Mean ± SEM, n = 5–6 donors per group.
∗P < 0.05; ∗∗P < 0.01 with respect to quiescent supernatants.
Figure 3. Growth inhibition by proteins or peptides. A, recombinant AMPs with A. baumannii (ATCC 19606), E. coli (ATCC 25922) or B. subtilis (ATCC 6633); B, recombinant
PF-4 formulations with A. baumannii (ATCC 19606); C, proteins identified by HPLC ECI-MS/MS with A. baumannii (ATCC 19606) or selected clinical isolates. Recombinant
IL-8, RANTES and Tβ4 (PeproTech, Rocky Hill, NJ), human or mouse PF-4 (PeproTech, Rocky Hill, NJ or R&D Systems, Minneapolis, MN), human PF-4 (58-70) (Bachem,
Torrance, CA), purified HP (Sigma Aldrich, St. Louis, NJ) and custom-synthesized TC-1 (NeoBioLab,Woburn, MA) were reconstituted in PBS containing 0.1% BSA. Purified
A2M and A2M-FF were buffered by the manufacturer (Athens Research, Athens, GA). ∗∗P < 0.01 with respect to controls containing the appropriate buffer.
Activity that inhibited growth by 40% was detected in two peaks
eluted in a NaCl gradient. High-performance liquid chromatog-
raphy/electrospray tandem mass spectrometry (University
of Texas Health Science Center, San Antonio, TX) identified two
proteins, alpha-2-macroglobulin and haptoglobin (HP).
HP is a natural bacteriostat affecting iron metabolism (Eaton
et al. 1982). Since HP levels in donor plasma were more than 10-
fold over those of normal plasma (Fig. 2), this concentration was
assayed for growth inhibition of the reference strain and three
clinical isolates. HP did not inhibit A. baumannii growth (Fig. 3c).
A2M is a non-specific protease inhibitor that occurs in a na-
tive form and in a proteolytically cleaved, electrophoretically
fast form (A2M-FF) (Rehman, Ahsan and Khan 2013). This pro-
tein was not quantified; however, it is not found in the platelet
proteome (Senzel, Gnatenko and Bahou 2009; Burkhart et al.
2012; van Holten et al. 2014; Zufferey et al. 2014), so the normal
plasma concentration of native A2M was assayed for each form.
While native A2M did not inhibit growth, two different lots of
A2M-FF inhibited the growth of the reference strain by 50%. This
activity was heat stable, supporting the concept that this pro-
tein comprised the heat-stable growth-inhibiting component of
donor plasma. However, neither form of A2M significantly inhib-
ited the growth of the clinical isolates. While native A2M has a
half-life in the circulation of several hours, A2M-FF is immedi-
ately endocytosed by hepatocytes andmacrophages, resulting in
a half-life of 2–4minutes (Rehman, Ahsan and Khan 2013). Since
hepatocytes are not present in donor plasma and macrophages
are present in only small numbers, A2M-FF may accumulate in
expired platelet plasma and potentially other stored serum or
plasma sample types. These proteins may stick to platelets and
therefore be present in platelet supernatants.
The potential antimicrobial mechanism of A2M is unknown.
The possibility of the direct generation of AMPswas investigated
computationally using by HHpred homology modeling (Soding
2005) and structure comparison in 3D-BLAST (Yang and Tung
2006). No apparent AMP motifs (Fjell et al. 2012) were found.
Alpha-2 macroglobulin shares about 35–40% homology to com-
plementmolecules C3, C4 and C5, which, during activation, gen-
erate AMPs known as anaphylatoxins (Pasupuleti et al. 2007).
Several conserved domains are shared by A2M and C3, C4 and
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Figure 4. Purification of the antimicrobial components of human platelet super-
natants. Samples were separated by size exclusion chromatography (Superdex
200, GE Healthcare, Pittsburgh, PA, USA). Antimicrobial activity was assayed
through entire elution volume, initially in the pools of five fractions and then
in individual fractions. A characteristic elution profile is depicted in blue, an-
timicrobial activity of corresponding pool fractions is overlayed in red. The inset
demonstrates the antimicrobial activity in individual fractions (n = 3).
C5. However, the canonical anaphylatoxin (ANATO) domain is
not found in the A2M sequence (DELTA-BLAST, National Center
for Biotechnology Information, USA). It is worth noting that the
region of the putative ANATO domain is not available for struc-
tural analysis. This region is disordered in the only available A2M
crystal structure (Protein Data Bank ID 4ACQ). Consequently, the
possibility of anaphylatoxin-like AMP production is uncertain
and requires further investigation.
In this study, we describe growth inhibition of a reference
strain and several clinical A. baumannii isolates by donor platelet
plasma components. As previously published, complement, a
heat-labile plasma component, was responsible for a percent-
age of this inhibition. Unexpectedly, platelet-derived AMPs did
not significantly inhibit growth. Sample fractionation, protein
identification and activity analysis implicated the fast form of
A2M in the growth inhibition of the reference strain only. These
results highlight the necessity of screening for potential antimi-
crobial effects with clinical rather than reference strains. A. bau-
mannii in particular is a genetically fluid organismable to acquire
virulence and resistance determinants (Gordon and Wareham
2010; Karah et al. 2012); some of these determinants may con-
tribute to the resistance to growth inhibition observed in these
isolates. The overall level of inhibition observed in donor plasma
was not recapitulated by the individual components, therefore,
undiscovered components, acting additively or synergistically,
probably contribute to growth inhibition.
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